MicroPort NeuroScientific grows revenue on overseas strength despite profit hit

The latest update is out from MicroPort NeuroTech Limited ( (HK:2172) ).

MicroPort NeuroScientific reported 2025 revenue of RMB790.5 million, up 3.8% year on year, driven mainly by strong 39.4% growth in overseas sales and expanding market share for its hemorrhagic stroke coil products. Despite this top-line progress and a 6% rise in non-HKFRS adjusted net profit to RMB298.5 million, reported net profit fell 26.2% to RMB183.8 million due to one-off, non-cash impairment and fair-value losses on an equity investment, though the board still proposed a final dividend of HK$0.09 per share.

The results underscore the company’s increasing reliance on international markets and product leadership in stroke treatment, set against the backdrop of a severe and growing global stroke burden, particularly in China where incidence and mortality remain among the highest in the world. This operational performance, coupled with continued profitability on an adjusted basis and a maintained dividend payout, suggests management’s confidence in the company’s underlying business momentum despite accounting-driven profit volatility.

The most recent analyst rating on (HK:2172) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.

More about MicroPort NeuroTech Limited

MicroPort NeuroScientific Corporation is a Cayman Islands–incorporated medical device company listed in Hong Kong that focuses on neurovascular interventions. Its primary products target hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke, with a growing emphasis on overseas markets including Asia Pacific, North America, Latin America, Europe, the Middle East and Africa.

Average Trading Volume: 6,697,990

Technical Sentiment Signal: Sell

Current Market Cap: HK$6.2B

See more data about 2172 stock on TipRanks’ Stock Analysis page.